BioCentury
ARTICLE | Finance

Smitten by SMID-caps

Why biotech buysiders are still bullish on small- and mid-caps

June 30, 2018 3:02 AM UTC

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course.

A politically charged environment is likely to intensify as the midterm elections approach in the U.S., and investors fully expect rhetoric around drug pricing to amplify as well...